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Abstract
Common variation on 14q24.1, close to RAD51B, has been associated with breast cancer:
rs999737 and rs2588809 with the risk of female breast cancer and rs1314913 with the risk
of male breast cancer. The aim of this study was to investigate the role of RAD51B variants
in breast cancer predisposition, particularly in the context of familial breast cancer in Fin-
land. We sequenced the coding region of RAD51B in 168 Finnish breast cancer patients
from the Helsinki region for identification of possible recurrent founder mutations. In addi-
tion, we studied the known rs999737, rs2588809, and rs1314913 SNPs and RAD51B hap-
lotypes in 44,791 breast cancer cases and 43,583 controls from 40 studies participating in
the Breast Cancer Association Consortium (BCAC) that were genotyped on a custom chip
(iCOGS). We identified one putatively pathogenic missense mutation c.541C>T among the
Finnish cancer patients and subsequently genotyped the mutation in additional breast can-
cer cases (n = 5259) and population controls (n = 3586) from Finland and Belarus. No signif-
icant association with breast cancer risk was seen in the meta-analysis of the Finnish
datasets or in the large BCAC dataset. The association with previously identified risk vari-
ants rs999737, rs2588809, and rs1314913 was replicated among all breast cancer cases
and also among familial cases in the BCAC dataset. The most significant association was
observed for the haplotype carrying the risk-alleles of all the three SNPs both among all
cases (odds ratio (OR): 1.15, 95% confidence interval (CI): 1.11–1.19, P = 8.88 x 10−16) and
among familial cases (OR: 1.24, 95% CI: 1.16–1.32, P = 6.19 x 10−11), compared to the hap-
lotype with the respective protective alleles. Our results suggest that loss-of-function muta-
tions in RAD51B are rare, but common variation at the RAD51B region is significantly
associated with familial breast cancer risk.
Introduction
Breast cancer is the most frequent cancer among women worldwide and also the leading cause
of cancer-related death [1]. Several susceptibility loci for breast cancer have been identified and
most of the currently known high- and moderate-penetrance predisposition genes have a role
in DNA repair. The major high-penetrance breast and ovarian cancer susceptibility genes
BRCA1 and BRCA2 are important for DNA double-strand break (DSB) repair through homol-
ogous recombination (HR) [2]. Proteins encoded by the moderate-penetrance genes ATM,
BRIP1, and CHEK2 interact with BRCA1 in DNA damage repair whereas PALB2 associates
with both BRCA1 and BRCA2 [2,3]. In the HR repair of DSBs, the RAD51 recombinase has a
key role. Binding of RAD51 to single-stranded DNA at the break site initiates the repair of a
DSB [4]. In humans, there are five RAD51 paralogs RAD51B, RAD51C, RAD51D, XRCC2,
and XRCC3, and they promote the binding of RAD51 to the DNA. Rare pathogenic mutations
in RAD51 paralogs RAD51C and RAD51D have been identified in breast and ovarian cancer
families and confer a high risk specifically for ovarian cancer [5–7] whereas a homozygous mis-
sense mutation in RAD51C (FANCO) was found in a Fanconi anemia patient [8]. A homozy-
gous XRCC2mutation has also been detected in a Fanconi anemia patient [9] and rare
mutations in the gene in breast cancer families were identified in an exome sequencing study
[10]; however, the association of XRCC2 with breast cancer risk could not be confirmed in a
large follow-up study [11].
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Variants in the RAD51B region, also known as RAD51L1, have been associated with breast
cancer risk in genome-wide association studies (GWAS) [12–14]. The major-allele of the com-
mon polymorphism rs999737 in intron 10 of RAD51B and the minor-allele of rs2588809 in
intron 7 have been associated with an increased risk of female breast cancer [12,14]. The
rs999737 has also been associated with breast cancer risk among BRCA1mutation carriers
whereas no association was found for rs999737 or rs2588809 with breast cancer subtypes
among BRCA1 or BRCA2mutation carriers [15,16]. Another common polymorphism located
in the intron 7 of the gene, rs1314913, has been associated with the risk of male breast cancer
[13]. RAD51B is located at 14q24.1 and is expressed widely, with the highest levels in tissues
that are active in recombination [17]. The RAD51B and RAD51C proteins form a stable com-
plex which interacts weakly with RAD51 and promotes the assembly of RAD51 nuclear foci
[18,19]. Furthermore, RAD51B is part of a larger BCDX2 complex that is formed with
RAD51C, RAD51D, and XRCC2 [4]. The BCDX2 complex acts upstream of RAD51 recruit-
ment to DNA damage foci [20]. Haploinsufficiency of RAD51B leads to aberrant HR repair of
DNA and causes centrosome fragmentation and aneuploidy in human cells which suggests
that loss of the proper biallelic expression of RAD51Bmay lead to chromosome instability in
tumor cells [21].
In the Finnish population, recurrent founder mutations have been observed in many of the
known breast and ovarian cancer susceptibility genes, including the RAD51 paralogs RAD51C
and RAD51D [22,23]. Thus, the Finnish population is a valuable resource for the identification
of new susceptibility alleles.
To identify putative recurrent founder mutations and to study the role of RAD51B in female
and male breast cancer predisposition and especially in familial breast cancer, we comprehen-
sively screened the RAD51B gene in 172 Finnish cancer patients. One identified missense
mutation was in silico predicted to be pathogenic and was subsequently screened in a larger set
of breast cancer cases and population controls from four datasets. In addition, the known
RAD51B risk SNPs rs999737, rs2588809, and rs1314913 and RAD51B haplotypes were studied
in the previously published 40 studies participating in the Breast Cancer Association Consor-
tium (BCAC) including 44,791 breast cancer cases and 43,583 controls.
Materials and Methods
Screening of the RAD51B gene
The coding region and the exon-intron boundaries of the RAD51B gene (RefSeq NG_023267.1,
NM_133509.3) were screened in 172 cancer patients from Southern Finland: in 87 female
breast cancer patients with a family history of female breast cancer or breast and ovarian can-
cer, in 4 familial ovarian cancer patients, and in 4 female breast cancer patients with a family
history of male and female breast cancer from the Helsinki region of Finland as well as in 77
male breast cancer patients (33 from the Helsinki region and 44 from the Tampere region) (S1
Text). All the female breast or ovarian cancer families and 60 of the male breast cancer families
and patients were previously screened negative for BRCA1/2mutations whereas 21 patients
had not been tested for BRCA1/2mutations. Genomic DNA isolated from blood was amplified
by PCR and subsequently sequenced using ABI BigDyeTerminator 3.1 Cycle Sequencing kit
(Life Technologies) (S1 Table). The sequencing results were analyzed with Variant Reporter
Software v1.0 (Life Technologies).
Genotyping of c.541C>T
The identified c.541C>T, p.(Arg181Trp) missense change was genotyped in additional familial
and unselected breast cancer patients and population controls from the Helsinki (cases = 2203,
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regions of Finland and in 1900 cases and 1235 controls from Belarus (S1 Text). The Helsinki
and Tampere datasets were genotyped by sequencing the exon 6 and the Oulu and Belarus
datasets by high-resolution-melting (HRM) analysis (S1 Table). Written informed consent was
obtained from all the participants and the study was approved by the Ethics Committees of
Helsinki University Hospital, Tampere University Hospital, Oulu University Hospital, and by
the institutional Ethics Commissions at the Minsk Mother and Child Hospital and at Hanno-
ver Medical School.
iCOGS genotyping
The common RAD51B polymorphisms rs2588809, rs1314913, and rs999737 were studied in
44,791 invasive breast cancer cases and 43,583 controls from 40 studies (including partially the
Helsinki, Oulu, and Belarus studies) participating in the Breast Cancer Association Consortium
(BCAC) (S2 Table) [14]. The SNPs were genotyped on the iCOGS array as part of the Collabo-
rative Oncological Gene-environment Study (COGS) as previously described [14] and geno-
types for the c.541C>T missense were imputed with SHAPEIT and IMPUTEv2 by using the
1000Genomes project as the reference panel [24]. The analyses were restricted to cases with
European ancestry. All participants gave written informed consent and all the studies were
approved by the respective Institutional Review Boards or Ethics Committees (S2 Table).
Bioinformatics and statistical methods
The pathogenicity of the variants identified in the sequencing of RAD51B was predicted using
the MutationTaster software as it considers both exonic and intronic variants [25]. In addition,
PON-P that utilizes results from SIFT, PhD-SNP, PolyPhen-2, SNAP, and I-Mutant 3 was
used to predict the pathogenicity of the missense variants [26]. Secondary structure prediction
was done with RaptorX [27] and protein-protein interaction with PredictProtein [28]. Statisti-
cal analyses were performed in R version 3.0.2 (http://www.r-project.org/). To study the associ-
ation of the c.541C>T mutation with breast cancer risk, two-sided P-values were calculated
using Pearson’s chi-squared test or, if the expected number of cell count was less than five,
Fisher’s exact test. For meta-analysis, the estimates were combined using a fixed-effects meta-
analysis, using the inverse variance-weighted method. Student’s t-test was used to compare the
age at diagnosis between the mutation carriers and non-carriers. Per-allele odds ratios (OR)
and confidence intervals (CI) for the common RAD51B polymorphisms were estimated with
logistic regression. Multivariate regression models including any two of the three SNPs at a
time were used to study the independence of the association signals. Haplotype-specific ORs
and CIs were estimated with the HaploStats package in R. A haplotype carrying the major-
alleles of rs2588809 and rs1314913 and the minor-allele of the rs999737 was used as a refer-
ence. Study and principal components were used as covariates in all analyses with the BCAC
dataset to correct for potential population stratification. The analyses for the genotyped SNPs
were adjusted for seven and the analysis for the imputed SNP for nine principal components as
previously described [14,24]. Separate analyses were performed for all breast cancer cases and
for subsets of cases with first-degree family history of breast cancer, and cases with estrogen
receptor (ER) positive and negative tumors. Studies where family history information was pre-
dominantly missing were excluded from the familial analyses. The imputed c.541C>T mis-
sense variant was analyzed with SNPTEST. First, an association test stratified with study was
performed to obtain imputation information scores for the individual studies. The final analy-
sis, restricted to BCAC studies with information score 0.5, was performed with study and the
nine principal components as covariates. The online tool LocusZoom was used to generate a
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Results
We sequenced the coding region and the exon-intron boundaries of the RAD51B gene in 168
breast (female and male) and 4 familial ovarian cancer patients from Southern Finland. Nine
intronic and six missense variants were identified (Table 1). The c.541C>T, p.(Arg181Trp),
missense change was the only variant that was predicted to be pathogenic by both MutationTa-
ster and PON-P software and was selected for further genotyping. Based on Finnish subjects in
the ExAC dataset, the minor-allele frequency (MAF) for the c.541C>T variant is estimated to
be 1.2% whereas in the non-Finnish Europeans the MAF is 0.05% (Exome Aggregation Con-
sortium (ExAC), Cambridge, MA (URL: http://exac.broadinstitute.org) [May, 2015]). Accord-
ing to RaptorX secondary structure prediction software the arginine in position 181 is located
in beta-sheet with the likelihood of 83.4% but, as determined by PredictProtein, the amino acid
is not predicted to directly participate in protein-protein interactions.
The c.541C>T missense variant was genotyped in additional 3359 female and male breast
cancer patients and families, and in 2351 population controls from Southern (Helsinki and Tam-
pere datasets) and Northern Finland (Oulu dataset). Altogether, when combining the two stages
of mutation testing, c.541C>T was screened in 2331 patients from Helsinki, 748 patients from
Tampere, and 452 patients fromOulu. There was no evidence of association in any of the popula-
tion-based case-control studies (Table 2). There was a suggestive association among breast cancer
families with at least three first or second-degree relatives affected with breast or ovarian cancer,
compared to population controls, in the Helsinki dataset (OR: 2.31, 95% CI: 1.20–4.48,
P = 0.010) (Table 2). The mean age at breast cancer diagnosis was similar between carriers and
Table 1. Variants identified in the screening of the RAD51B gene (RefSeq NM_133509.3).
DNA change protein change rs-number position AA a Aa b Aa c MAF d MAFExAC
e MutationTaster PON-P
c.84+28T>G rs17783124 intron 2 71 84 17 0.343 0.287 polymorphism
c.84+82T>C rs28604984 intron 2 71 84 17 0.343 polymorphism
c.84+120G>A rs28623567 intron 2 71 84 17 0.343 polymorphism
c.199-33G>T rs184815928 intron 3 170 2 0 0.006 0.007 polymorphism
c.199-30dupA rs34564590 intron 3 70 85 17 0.346 0.286 polymorphism
c.199-21C>T rs35183950 intron 3 171 1 0 0.003 0.002 polymorphism
c.515T>G p.Leu172Trp rs34094401 exon 6 167 5 0 0.015 0.027 polymorphism unclassiﬁed
c.539A>G p.Tyr180Cys rs28910275 exon 6 145 27 0 0.078 0.057 polymorphism unclassiﬁed
c.541C>T p.Arg181Trp rs199981178 exon 6 169 3 0 0.009 0.012 disease causing pathogenic
c.572+95_96delGG intron 6 171 1 0 0.003 polymorphism
c.728A>G p.Lys243Arg rs34594234 exon 7 167 4 1 0.017 0.008 disease causing unclassiﬁed
c.854-103A>G rs10146321 intron 8 104 64 4 0.209 polymorphism
c.957+125C>A rs10146772 intron 9 48 83 41 0.480 polymorphism
c.1063G>A p.Ala355Thr rs61758785 exon 11 170 2 0 0.006 0.007 polymorphism neutral
c.1094C>G p.Pro365Arg rs28908468 exon 11 140 32 0 0.093 0.115 polymorphism NA
Counts of a common homozygotes
b heterozygotes and
c rare homozygotes in this study
d Minor-allele frequency (MAF) in this study
e MAF in the Finnish population in the ExAC database
doi:10.1371/journal.pone.0153788.t001
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non-carriers among the familial patients (54.2 for carriers and 53.1 for non-carriers, P = 0.725)
and among all cases (55.9 for carriers and 56.4 for non-carriers, P = 0.744). However, no associa-
tion was observed for familial breast cancer in the Oulu dataset, and there was no evidence of
association when all datasets were combined (OR: 1.35, 95% CI: 0.66–2.73, P = 0.410). The vari-
ant was also genotyped in 1900 breast cancer cases and 1235 population controls from Belarus
but only three carriers were identified among cases and none among controls (Table 2).
We further studied the missense variant c.541C>T and the previously reported common
risk SNPs rs2588809, rs1314913, and rs999737 in a large breast cancer dataset from BCAC
comprising 40 studies with 44,791 invasive breast cancer cases and 43,583 controls of predomi-
nantly European ancestry. The subjects were genotyped on an Illumina Infinium custom chip
(iCOGS) for over 200,000 SNPs [14], including the rs2588809, rs1314913, and rs999737 SNPs.
Genotypes for over 11 million SNPs, including the c.541C>T missense variant, were imputed
by using the 1000Genomes project as a reference panel [24]. For the missense variant, we first
performed an association test stratified by study including all the 40 BCAC studies. The overall
information score for the c.541C>T was 0.673. To increase the imputation accuracy of this
rare variant, studies with information score less than 0.5 in the stratified analysis were excluded
from the final analysis (S3 Table). Altogether 26,969 cases and 27,092 controls from 23 studies
were included and the information score for the variant in the final analysis was 0.755. The
Table 2. Frequencies and ORs for the c.541C>Tmutation among the different patient subgroups in the Helsinki, Tampere, Oulu, and Belarus
series.
HELSINKI dataset Total CC % CT % OR (95% CI) P
Controls 1278 1257 98.36% 21 1.64%
All female BC cases 2293 2240 97.69% 53 2.31% 1.42 (0.85–2.36) 0.179
Familial BC (3 affected)a 430 414 96.28% 16 3.72% 2.31 (1.20–4.48) 0.010
Familial BC (2 affected) b 523 513 98.09% 10 1.91% 1.17 (0.55–2.50) 0.690
Unselected BC 1728 1690 97.80% 38 2.20% 1.35 (0.79–2.30) 0.277
Male BC c 37 36 97.30% 1 2.70% 1.66 (0.22–12.70) 0.469
Familial OC 4 4 100% 0 0% - 1
TAMPERE dataset Total CC % CT/TT d % OR (95% CI) P
Controls 800 778 97.25% 22 2.75%
Unselected BC 645 620 96.12% 25 3.88% 1.43 (0.80–2.55) 0.230
Male BC e 103 102 99.03% 1 0.97% 0.35 (0.05–2.60) 0.503
OULU dataset Total CC % CT % OR (95% CI) P
Controls 273 267 97.80% 6 2.20%
All female BC cases 452 443 98.01% 9 1.99% 0.90 (0.32–2.57) 0.850
Familial BC (3 affected)a 83 82 98.80% 1 1.20% 0.54 (0.06–4.57) 1
Familial BC (2 affected) b 49 48 97.96% 1 2.04% 0.93 (0.11–7.87) 1
Unselected BC 320 313 97.81% 7 2.19% 1.00 (0.33–3.00) 0.993
BELARUS dataset Total CC % CT % OR (95% CI) P
Controls 1235 1235 100% 0 0% -
BC cases 1900 1897 99.85% 3 0.15% - 0.284
BC = breast cancer; OC = ovarian cancer
a Families with 3 BC or OC among ﬁrst- or second-degree relatives
b Two ﬁrst-degree relatives affected with BC or OC
c Includes 33 male BC cases and 4 female BC cases with family history of male BC
d The Tampere dataset included one case with homozygous mutation
e Male BC cases only
doi:10.1371/journal.pone.0153788.t002
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MAF of the c.541C>T missense variant was 0.2% among all cases, familial cases, and controls
and it did not associate with breast cancer among all cases (OR: 0.97, 95% CI: 0.76–1.25,
P = 0.538) or familial cases (OR: 1.04, 95% CI: 0.65–1.66, P = 0.794). The highest frequency
was observed in the Finnish studies HEBCS, KBCP, and OBCS with the overall MAF ranging
from 0.6% to 0.7%. The HEBCS and OBCS studies are overlapping with the Finnish Helsinki
and Oulu datasets that were genotyped for the variant.
Breast cancer associations for two of the genotyped SNPs, rs2588809 and rs999737, in the
BCAC dataset have been published before [14,24,30] and the results were replicated here. The
minor-alleles of rs2588809 and rs1314913 and the major-allele of rs999737 were associated
with an increased risk of breast cancer with ORs between 1.07–1.08 among all breast cancer
cases and also among familial cases with ORs between 1.10–1.15 (Table 3). The associations
were also significant among the subset of cases with ER-positive tumors but only rs999737
showed association among the ER-negative subset (Table 3). Rs2588809 and rs1314913 are
strongly correlated (r2 = 0.816), whereas rs999737 is not correlated with them (r2 = 0.003 with
rs2588809 and r2 = 0.070 with rs1314913) (S1 Fig). In multivariate logistic regression models,
both rs2588809 and rs1314913 remained significant after adjustment with rs999737 (OR: 1.07,
95% CI: 1.04–1.09, P = 1.74 x 10−6 and OR: 1.06, 95% CI: 1.03–1.09, P = 9.24 x 10−6, respec-
tively). Likewise, rs999737 remained an independent predictor for risk after adjustment with
rs2588809 or rs1314913 (OR: 1.08, 95% CI: 1.06–1.11, P = 2.91 x 10-11and P = 2.54 x 10−11,
respectively). Neither rs2588809 nor rs1314913 remained significant when adjusted with each
other (OR: 1.07, 95% CI: 1.00–1.16, P = 0.066 and OR: 1.00, 95% CI: 0.93–1.08, P = 0.977,
respectively).
To evaluate the allele combination associated with the highest risk, we performed haplotype
analysis for rs2588809, rs1314913, and rs999737. The reference haplotype CCT, carrying the
major-alleles of rs2588809 and rs1314913 and the minor-allele of rs999737 had an estimated
frequency of 21.0% among controls and 19.4% among cases. The strongest association was
observed for the TTC haplotype that carries the risk-alleles of all the three SNPs with an odds
ratio of 1.15 for all cases (95% CI: 1.11–1.19, P = 8.88 x 10−16) and 1.24 for familial cases (95%
CI: 1.16–1.32, P = 6.19 x 10−11) (Table 4). This haplotype had an estimated frequency of 12.6%
among controls, 13.5% among all cases, and 14.1% among familial cases. The most common
haplotype, with over 60% frequency among cases and controls, was the haplotype CCC carry-
ing the risk-allele of rs999737 and also this haplotype associated with an increased risk of breast
cancer among all the cases (OR: 1.09, 95% CI: 1.06–1.12, P = 1.86 x 10−10) and the familial
cases (OR: 1.14, 95% CI: 1.09–1.20, P = 1.30 x 10−7) when compared to the CCT haplotype.
Discussion
To study the role of RAD51B in breast cancer predisposition, we screened the coding sequence
in 172 Finnish breast or ovarian cancer patients. We also studied the common susceptibility
variants in the genomic region of the gene in a large dataset from BCAC including 44,791
Table 3. Frequencies and ORs for the SNPs rs2588809, rs1314913, and rs999737 for all breast cancer cases, familial cases and ER-positive and
-negative cases in the BCAC dataset.
Rs-number MAF controls MAF cases ORALL (95%CI) PALL ORFAM (95%CI) PFAM ORER+ (95%CI) PER+ ORER- (95%CI) PER-
rs2588809 0.158 0.169 1.08 (1.05–1.10) 4.62 x 10−8 1.10 (1.05–1.16) 9.72 x 10−5 1.09 (1.06–1.12) 1.65 x 10−8 1.00 (0.95–1.05) 8.90 x 10−1
rs1314913 0.144 0.154 1.07 (1.04–1.10) 2.74 x 10−7 1.10 (1.04–1.16) 2.45 x 10−4 1.09 (1.05–1.12) 1.36 x 10−7 0.98 (0.93–1.03) 3.85 x 10−1
rs999737 0.231 0.215 1.09 (1.06–1.11) 7.78 x 10−13 1.15 (1.10–1.20) 1.08 x 10−9 1.10 (1.07–1.13) 7.70 x 10−12 1.05 (1.00–1.10) 3.03 x 10−2
ALL = all breast cancer cases; FAM = familial breast cancer cases; ER+ = ER-positive; ER- = ER- negative.
doi:10.1371/journal.pone.0153788.t003
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breast cancer cases and 43,583 controls. Among the Finnish patients, we identified one puta-
tively pathogenic missense variant, c.541C>T, p.(Arg181Trp), that was further screened in a
larger set of unselected and familial breast cancer patients and population controls.
In the Helsinki dataset, the c.541C>T mutation had a suggestive association with familial
breast cancer but this association was not confirmed in the other Finnish sample sets. In Bela-
rus, the mutation was rare and was identified only in three cases but not among controls. For
the large BCAC dataset that had been genotyped on the iCOGS chip, c.541C>T genotypes
were imputed. The missense was very rare with a 0.2% MAF and no association with breast
cancer was seen among all breast cancer cases or in the subset of familial patients.
Out of the common variants at the RAD51B region, rs999737 and rs2588809 have been
associated with female breast cancer and rs1314913 with male breast cancer [12–14,30]. For
rs999737 and rs2588809 the results from the previous BCAC studies for all cases and by ER sta-
tus were replicated here [14,30]. The rs1314913 SNP has been previously associated with male
breast cancer with an OR of 1.57 (P = 3.02 × 10−13) [13]. It has not been previously reported in
female breast cancer, and showed here similar associations as rs2588809 with OR of 1.07
among all cases and 1.09 among ER-positive cases. The rs1314913 SNP is correlated with
rs2588809 (r2 = 0.816) but not with rs999737 (r2 = 0.070). Our results suggest two independent
associations at the region as rs999737 adjusted with rs1314913 or rs2588809 showed significant
association whereas neither rs1314913 nor rs2588809 remained significant after adjustment
with each other, suggesting both may be tagging another, causative allele.
All three variants were also associated with familial breast cancer. The strongest association
was observed for a haplotype carrying the risk-alleles of all the three SNPs both among all cases
and familial cases with ORs of 1.15 and 1.24, respectively. This haplotype is observed at a fre-
quency of 12.6% among controls and 13.5% among cases.
To date, only three studies have reported truncating germline mutations in RAD51B: two
deleterious mutations were detected among ovarian cancer cases, one splicing mutation in a
breast and ovarian cancer family, and one nonsense mutation in a melanoma family [31–33].
In an Australian, study no pathogenic mutations were identified among 188 breast cancer fam-
ilies [34]. These reports together with our results suggest that loss-of-function mutations in
RAD51B are very rare yet we cannot exclude such mutations and possibly a higher breast can-
cer risk associated with these. However, the common variants in the RAD51B region are associ-
ated with an increased breast cancer risk. Further fine-mapping studies are needed to identify
the causative variants underlying the associations, and functional studies to determine whether
RAD51B or another gene in the region is the target of these associations. RAD51B is a plausible
candidate gene for the association as it functions in HR repair of DNA damage like most of the
known breast cancer genes.
Table 4. Estimated haplotype frequencies and haplotype-specific ORs among the BCAC dataset. The haplotypes are based on genotypes for SNPs
rs2588809, rs1314913, and rs999737.
All breast cancer cases Familial breast cancer cases
Haplotype Freq controls Freq cases OR (95% CI) P Freq controls Freq cases OR (95% CI) P
CCT (reference) 0.210 0.194 0.211 0.188
TTC 0.126 0.135 1.15 (1.11–1.19) 8.88 x 10−16 0.126 0.141 1.24 (1.16–1.32) 6.19 x 10−11
CCC 0.632 0.636 1.09 (1.06–1.12) 1.86 x 10−10 0.628 0.635 1.14 (1.09–1.20) 1.30 x 10−7
TCC 0.011 0.013 1.15 (1.04–1.27) 5.48 x 10−3 0.012 0.013 1.17 (0.98–1.41) 8.36 x 10−2
TTT 0.018 0.018 1.11 (0.99–1.23) 7.12 x 10−2 0.018 0.017 1.06 (0.86–1.31) 5.70 x 10−1
Freq = frequency
doi:10.1371/journal.pone.0153788.t004
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In conclusion, no pathogenic RAD51Bmutations were identified among 172 Finnish breast
or ovarian cancer patients. However, we cannot rule out rare risk-variants in the Finnish or
other populations. The minor-alleles of the common polymorphisms rs2588809 and
rs1314913 and the major-allele of rs999737 were associated with breast cancer risk in the large
BCAC dataset. The strongest association was observed for a risk haplotype carrying the risk-
alleles of all the three SNPs with an OR of 1.15 among all cases and 1.24 among familial cases
compared to the haplotype with the respective protective alleles.
Supporting Information
S1 Fig. Regional association plot for the RAD51B SNPs rs2588809, rs1314913, and
rs999737 and the c.541C>T missense variant. Each variant is represented with a dot and the
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